Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Page 1
Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis.
van Es N, Takada T, Kraaijpoel N, Klok FA, Stals MAM, Büller HR, Courtney DM, Freund Y, Galipienzo J, Le Gal G, Ghanima W, Huisman MV, Kline JA, Moons KGM, Parpia S, Perrier A, Righini M, Robert-Ebadi H, Roy PM, Wells PS, de Wit K, van Smeden M, Geersing GJ. van Es N, et al. Among authors: wells ps. Eur Heart J. 2023 Aug 22;44(32):3073-3081. doi: 10.1093/eurheartj/ehad417. Eur Heart J. 2023. PMID: 37452732 Free PMC article.
The final model included age (in years), sex, previous VTE, recent surgery or immobilization, haemoptysis, cancer, clinical signs of deep vein thrombosis, inpatient status, D-dimer (in g/L), and an interaction term between age and D-dimer. The pooled c-statistic was 0.87 ( …
The final model included age (in years), sex, previous VTE, recent surgery or immobilization, haemoptysis, cancer, clinical signs of deep ve …
The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.
Caiano L, Kovacs MJ, Lazo-Langner A, Anderson DR, Kahn SR, Shah V, Kaatz S, Zide RS, Schulman S, Chagnon I, Mallick R, Rodger MA, Wells PS. Caiano L, et al. Among authors: wells ps. J Thromb Haemost. 2023 Mar;21(3):553-558. doi: 10.1016/j.jtha.2022.12.021. Epub 2022 Dec 30. J Thromb Haemost. 2023. PMID: 36710196 Free article.
METHODS: This multicentre, multinational, prospective cohort study evaluated adults receiving long-term anticoagulants after a VTE event. We analyzed the incidence of major bleeding as the primary outcome, according to the genotype for FVL and PGM (wild-type and heterozygo …
METHODS: This multicentre, multinational, prospective cohort study evaluated adults receiving long-term anticoagulants after a VTE ev …
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis.
Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, Büller HR, Raskob GE, Ageno W, Couturaud F, Prandoni P, Palareti G, Legnani C, Kyrle PA, Eichinger S, Eischer L, Becattini C, Agnelli G, Vedovati MC, Geersing GJ, Takada T, Cosmi B, Aujesky D, Marconi L, Palla A, Siragusa S, Bradbury CA, Parpia S, Mallick R, Lensing AWA, Gebel M, Grosso MA, Thavorn K, Hutton B, Le Gal G, Fergusson DA, Rodger MA; MAJESTIC Collaborators. Khan F, et al. Among authors: wells ps. Ann Intern Med. 2021 Oct;174(10):1420-1429. doi: 10.7326/M21-1094. Epub 2021 Sep 14. Ann Intern Med. 2021. PMID: 34516270
BACKGROUND: The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain. ...CONCLUSION: In patients with a first unprovoked VTE, the long-t …
BACKGROUND: The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant the …
Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.
Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, Büller HR, Raskob GE, Ageno W, Couturaud F, Prandoni P, Palareti G, Legnani C, Kyrle PA, Eichinger S, Eischer L, Becattini C, Agnelli G, Vedovati MC, Geersing GJ, Takada T, Cosmi B, Aujesky D, Marconi L, Palla A, Siragusa S, Bradbury CA, Parpia S, Mallick R, Lensing AWA, Gebel M, Grosso MA, Shi M, Thavorn K, Hutton B, Le Gal G, Rodger M, Fergusson D. Khan F, et al. Among authors: wells ps. J Thromb Haemost. 2021 Nov;19(11):2801-2813. doi: 10.1111/jth.15491. Epub 2021 Aug 22. J Thromb Haemost. 2021. PMID: 34379859 Free article.
BACKGROUND: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain. ...CONCLUSIONS: In patients with a first unprovoked VTE, the long-term risk of recurrent VTE during extended anticoagul …
BACKGROUND: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE …
Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study.
Aziz D, Skeith L, Rodger MA, Sabri E, Righini M, Kovacs MJ, Carrier M, Kahn SR, Wells PS, Anderson DR, Chagnon I, Solymoss S, Crowther MA, White RH, Le Gal G. Aziz D, et al. Among authors: wells ps. J Thromb Haemost. 2021 Jun;19(6):1526-1532. doi: 10.1111/jth.15303. Epub 2021 Apr 21. J Thromb Haemost. 2021. PMID: 33724705 Free article.
INTRODUCTION: The risk of recurrent venous thromboembolism (VTE) after combined oral contraceptive (COC) use is variably reported. We assessed the long-term risk of recurrent VTE in women on COC at the time of a first VTE, in comparison to women without COC use. ...CONCLUS …
INTRODUCTION: The risk of recurrent venous thromboembolism (VTE) after combined oral contraceptive (COC) use is variably reported. We assess …
Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.
Ma KA, Kahn SR, Akaberi A, Dennie C, Rush C, Granton JT, Anderson D, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Hernandez P, Aaron SD, Pena E, Abikhzer G, Hirsch AM; ELOPE Study group. Ma KA, et al. Among authors: wells ps. Res Pract Thromb Haemost. 2018 Jun 17;2(4):670-677. doi: 10.1002/rth2.12123. eCollection 2018 Oct. Res Pract Thromb Haemost. 2018. PMID: 30349885 Free PMC article.
As a planned sub-study of the prospective, multicenter ELOPE (Evaluation of Long-term Outcomes after PE) Study, we aimed to describe the results of serial imaging by computed tomography pulmonary angiography (CTPA) and perfusion scan during 1 year after a first episode of …
As a planned sub-study of the prospective, multicenter ELOPE (Evaluation of Long-term Outcomes after PE) Study, we aimed to describe …
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberté F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P. Wells PS, et al. Chest. 2018 Dec;154(6):1371-1378. doi: 10.1016/j.chest.2018.08.1059. Epub 2018 Sep 7. Chest. 2018. PMID: 30201406 Free article.
BACKGROUND: Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study assessed cost impact of continued anticoagulation therapy with rivaroxaban vs aspirin. ...
BACKGROUND: Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism …
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P. Wells PS, et al. J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16. J Med Econ. 2018. PMID: 29469638 Free article. Clinical Trial.
LIMITATIONS: This study was conducted over the 1-year observation period of the EINSTEIN-EXT trial, which limited "real-world" applicability and examination of long-term economic impact. Assumptions on drug and clinical event costs were US-based and, thus, not applicable t …
LIMITATIONS: This study was conducted over the 1-year observation period of the EINSTEIN-EXT trial, which limited "real-world" applicability …
Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis.
Bikdeli B, Sharif-Kashani B, Bikdeli B, Valle R, Falga C, Riera-Mestre A, Mazzolai L, Verhamme P, Wells PS, Torrero JFSM, Lopez-Jiménez L, Monreal M; RIETE Investigators. Bikdeli B, et al. Among authors: wells ps. Semin Thromb Hemost. 2018 Jun;44(4):341-347. doi: 10.1055/s-0037-1621716. Epub 2018 Jan 12. Semin Thromb Hemost. 2018. PMID: 29329472 Free PMC article.
Compared with those with left-sided DVT, patients with right-sided DVT have slightly higher rates of PE. Bilateral DVT is associated with markedly worse short-term and 1-year outcomes....
Compared with those with left-sided DVT, patients with right-sided DVT have slightly higher rates of PE. Bilateral DVT is associated with ma …
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
Weeda ER, Peacock WF, Fermann GJ, Baugh CW, Wells PS, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Weeda ER, et al. Among authors: wells ps. Int J Clin Pract. 2017 Jan;71(1). doi: 10.1111/ijcp.12915. Int J Clin Pract. 2017. PMID: 28097761
CONCLUSION: Rivaroxaban was associated with shortened LOS and lowered cost vs parenterally bridged warfarin in PE observation stay patients, without increases in the short-term rate of complications or readmission....
CONCLUSION: Rivaroxaban was associated with shortened LOS and lowered cost vs parenterally bridged warfarin in PE observation stay patients, …
35 results